JDM  Vol.4 No.1 , February 2014
Role of toll receptors in diabetic nephropathy
Abstract: Objectives: Diabetic nephropathy is the leading cause of chronic kidney disease. The pathogenesis of DN remains incompletely understood. It has been recently demonstrated that inflammatory processes play a significant role in the development and progression of DN. Toll-like receptors play a fundamental role in the innate immune system by triggering proinflammatory signaling pathways. Our aim is to evaluate the expression of TLRs on monocytes and relate their expression with inflammation in HD patients with & without diabetic nephropathy. Method: In a case control study (60) patients from Alkasr El Aini Hospital on hemodialysis were divided into two groups: Group 1, 30 patients on heamodialysis not due to diabetic nephropathy, Group 2, 30 patients on heamodialysis due to diabetic nephropathy, compared to Group 3, including 30 healthy controls. All participants were subjected to: Full medical history, complete physical examination, Serum creatinine, uric acid, A1C, fundus examination, detection of TLR2, TLR expression by real time PCR in peripheral blood mononuclear cells. Data were statically calculated using SPSS, comparision between groups was done using student T test comparing 2 groups, correlation using spearman’s correlation. Results: Diabetic had significantly increased TLR2, TLR4 mRNA in peripheral blood mononuclear cells compared to controls and non diabetics patient on heamodialysis (p < 0.001), TLR2, TLR4 significantly correlated with dialysis duration in diabetic (p < 0.001), no correlation with A1C in relation to TLR2 (p = 0.078), TLR4 (p = 0.163). Conclusion: TLR2, TLR4 were significantly elevated in diabetic on dialysis initiating event in the pathogenesis of DN, providing a link between hyperglycemia and hypoxia with inflammation and fibrosis within the kidney. Hence, therapeutic interventions aimed at targeting the inflammatory component through interruption of TLR signaling may be a novel strategy to target prevention and treatment of DN.
Cite this paper: Mansour, M. , Salam, R. , Rashed, L. and Salam, H. (2014) Role of toll receptors in diabetic nephropathy. Journal of Diabetes Mellitus, 4, 26-32. doi: 10.4236/jdm.2014.41005.

[1]   Zimmet, P., Alberti, K. and Shaw, J. (2001) Global and societal implications of the diabetes epidemic. Nature, 414, 782-787.

[2]   Navarro, J.F., Milena, F.J., Mora, C., Leon, C. and García, J. (2006) Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: Effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. American Journal of Nephrology, 26, 562-570. 1159/000098004

[3]   Beutler, B. (2004) Inferences, questions and possibilities in Toll-like receptor signalling. Nature, 430, 257-263.

[4]   Cunningham, P.N., Wang, Y., Guo, R., He, G. and Quigg, R.J. (2004) Role of toll-like receptor 4 in endotoxin-induced acute renal failure. The Journal of Immunology, 172, 2629-2635.

[5]   Devaraj, S., Dasu, M.R., Park, S.H. and Jialal, I. (2009) Increased levels of ligands of Toll-like receptors 2 and 4 in Type 1 diabetes. Diabetologia, 52, 1665-1668. s00125-009-1394-8

[6]   Mark, E.C., Karim, J.-D. and Merlin, C.T. (2005) Targets to retard the progression of diabetic nephropathy. Kidney International, 68, 1439-1445. 00555.x

[7]   Ramirez, S.R. and Dasu, M. R.K. (2012) Toll-like receptors and diabetes complications: Recent advances. Current Diabetes Reviews, 8, 480-488.

[8]   Campbell, R.C., Ruggenenti, P. and Remuzzi, G. (2002) Halting the progression of chronic nephropathy. Journal of the American Society of Nephrology, 13, S190-S195. 1097/01.ASN.0000032522.29672.0A

[9]   An, J.H., Cho, Y.M., Yu, H.G., Jang, H.C., Park, K.S., Kim, S.Y. and Lee, H.K. (2009) The clinical characteristics of normoalbuminuric renal insufficiency in Korean Type 2 diabetic patients: A possible early stage renal complication. Journal of Korean Medical Science, 24, S75-S81.

[10]   Ruggenentim, P. and Remuzzi, G. (2007) Kidney failure stabilizes after a two-decade increase: Impact on global (renal and cardiovascular) health. Clinical Journal of the American Society of Nephrology, 2, 146-150.

[11]   Wong, F.S. and Wen, L. (2008) Toll-like receptors and diabetes. Annals of the New York Academy of Sciences, 1150, 123-132.

[12]   Uematsu, S. and Akira, S. (2006) Toll-like receptors and innate immunity. Journal of Molecular Medicine, 84, 712-725.

[13]   Chiu, Y. C., Lin, C. Y., Chen, C. P., Huang, K. C., Tong, K.M., Tzeng, C. Y., Lee, T. S., Hsu, H. C. and Tang, C.-H. (2009) Peptidoglycan enhances IL-6 production in human synovial fibroblasts via TLR2 receptor, focal adhesion kinase, Akt, and AP-1dependent pathway. The Journal of Immunology, 183, 2785-2792.

[14]   Dasu, M.R., Devaraj, S., Park, S. and Jialal, I. (2010) Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed Type 2 diabetic subjects. Diabetes Care, 33, 861-868.

[15]   Schwartz, E.A., Zhang, W.Y., Karnik, S.K., Borwege, S., Anand, V.R., Laine, P.S., Su, Y. and Reaven, P.D. (2010) Nutrient modification of the innate immune response: A novel mechanism by which saturated fatty acids greatly amplify monocyte inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 30, 802-808.

[16]   Mohammad, M.K., Morran, M., Slotterbeck, B., Leaman, D.W., Sun, Y., Grafenstein, H., Hong, S.C. and McInerney, M.F. (2006) Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse. International Immunology, 18, 1101-1113.

[17]   Creely, S.J., McTernan, P.G., Kusminski, C.M. et al. (2007) Lipo polysaccharide activates an innate immune system response in human adipose tissue in obesity and Type 2 diabetes. American Journal of Physiology: American Journal of Physiology, 292, 740-747. 00302.2006

[18]   Song, M.J., Kim, K.H., Yoon, J.M. and Kim, J.B. (2006) Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochemical and Biophysical Research Communications, 346, 739-74521.

[19]   Beutler, B. (2004) Inferences, questions and possibilities in Toll-like receptor signalling. Nature, 430, 257-263.

[20]   Li, H. and Sun, B. (2007) Toll-like receptor 4 in atherosclerosis. Journal of Cellular and Molecular Medicine, 11, 88-95.

[21]   Dounousi, E., Koliousi, E., Papagianni, A., Ioannou, K., Zikou, X., Katopodis, K., Kelesidis, A., Tsakiris, D. and Siamopoulos, K.C. (2012) Mononuclear leukocyte apoptosis and inflammatory markers in patients with chronic kidney disease. American Journal of Nephrology, 36, 531-536.

[22]   Lin, M., Yiu, W.H., Wu, H.J., Chan, L.Y., Leung, J.C., Au, W.S., Chan, K.W., Lai, K.N. and Tang, S.C. (2010) Tolllike receptor 4 promotes tubular inflammation in diabetic nephropathy. American Journal of Nephrology, 23, 86-102.

[23]   Dasu, M.R., Ramirez, S. and Isseroff, R.R. (2010) Tolllike receptors and diabetes: A therapeutic perspective. Clinical Science, 122, 203-214

[24]   Devaraj, S., Tobias, P., Kasinath, B.S., Ramsamooj, R., Afify, A. and Jialal, I. (2011) Knockout of toll-like receptor-2 attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy. Arteriosclerosis, Thrombosis, and Vascular Biology, 31, 1796-1804.